Mamu-B*17+ rhesus macaques vaccinated 1 with env, vif, and nef manifest early control of SIVmac239 replication

AUTHORS - Mauricio A. Martins1*, Damien C. Tully2, Nuria Pedreno-Lopez1, Benjamin von Bredow3 ,Matthias G. Pauthner4, Young C. Shin1, Maoli Yuan5, Noemia S. Lima6, David J. Bean2 , LucasGonzalez-Nieto1, Aline Domingues1, Martin J. Gutman1, Helen S. Maxwell1, Diogo M. Magnani1 ,Michael J. Ricciardi1, Varian K. Bailey1, John D. Altman7, Dennis R. Burton2,4, Keisuke Ejima8 ,David B. Allison8, David T. Evans3,9, Eva G. Rakasz9, Christopher L. Parks5, Myrna C. Bonaldo6 ,Saverio Capuano III9, Jeffrey D. Lifson10, Ronald C. Desrosiers1, Todd M. Allen2 , David I.Watkins1 - AFFILIATIONS - 1 Department of Pathology, University of Miami, Miami, Florida, USA. 2 Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA 3 Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA 4 Department of Immunology and Microbiology; IAVI Neutralizing Antibody Center; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID); The Scripps Research Institute, La Jolla, California, USA., 5 International AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory,Brooklyn, New York, USA, 6 Laboratorio de Biologia Molecular de Flavivirus, Instituto Oswaldo Cruz–FIOCRUZ, Rio de Janeiro, Brazil 7 Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA 8 School of Public Health, 24 Indiana University-Bloomington, Bloomington, Indiana, USA 9 Wisconsin National Primate Research Center, University of Wisconsin–Madison, Madison, Wisoncin, USA 10 AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.